Cognition Therapeutics, Inc. (CGTX) Dividend History

Company News

• These Were the 5 Top-Performing Stocks in the Nasdaq Composite in August 2025

  Five Nasdaq-listed stocks significantly outperformed the index in August, with gains ranging from 188% to 378%, driven by factors like drug development progress, FDA approvals, and strategic partnerships.

  The Motley Fool

  Featured Companies: EQ IPDN THAR
• Cognition Therapeutics Closes $30 Million Registered Direct Offering to Two New Fundamental Institutional Investors, Including a Preeminent Global Investment Firm to Support Phase 3 Development of Zervimesine (CT1812)

  Cognition Therapeutics raised $30 million through a registered direct offering of 14.7 million common stock shares at $2.05 per share, with proceeds intended to support Phase 3 development of zervimesine for neurodegenerative disorders.

  GlobeNewswire Inc.
• Cognition Therapeutics And 2 Other Stocks Under $2 Insiders Are Buying

  The Dow Jones index closed lower by more than 100 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform. Blue Star Foods The Trade: Blue Star Foods Corp. (NASDAQ: BSFC) Director Nubar Herian acquired a total of 219,611 shares an average price of $0.14. To acquire these shares, it cost ...

  Benzinga

  Featured Companies: EKSO
• Is Accelerate Diagnostics (AXDX) Outperforming Other Medical Stocks This Year?

  Here is how Accelerate Diagnostics (AXDX) and Cognition Therapeutics, Inc. (CGTX) have performed compared to their sector so far this year.

  Zacks Investment Research